ArticleEuropean journal of pediatrics2026
Clinical and immunological predictors of baked egg tolerance in children with IgE-mediated hen's egg allergy: a cross-sectional diagnostic accuracy study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baked egg (BE) introduction in IgE-mediated hen's egg allergy (HEA) is a practical strategy for dietary diversification and may promote future tolerance to hen's egg. This study aims to characterise clinical and immunological profile of children with HEA undergoing BE oral food challenge (BE-OFC) and to evaluate the individual and combined predictive performance of serum-specific IgE (sIgE), skin prick test (SPT), and basophil activation test (BAT) for BE tolerance. This is a cross-sectional diagnostic accuracy study of children aged 12 months to less than 6 years with confirmed IgE-mediated HEA attending a tertiary referral centre in Barcelona. All participants underwent standardised open BE-OFC. Receiver operating characteristic (ROC) analysis was used to evaluate biomarker performance. Exploratory associations with BE tolerance were examined using Firth's penalised logistic regression. Fifty-one children completed BE-OFC; 56.9% were tolerant. Tolerance was lower in those with prior anaphylaxis (35.7% vs 64.9%), without statistical significance (p = 0.111). During BE-OFC, epinephrine was required in only two of 22 non-tolerant patients. Ovomucoid (OVM)-sIgE was the best-performing single biomarker (AUC 0.71; 95% CI 0.55-0.87; cutoff 4.48 kUA/L; sensitivity 68.2%; specificity 79.3%). Tolerant patients demonstrated lower BAT net stimulation responses across egg white concentrations. Neither SPT nor BAT markers achieved meaningful discrimination. In adjusted analyses, OVM-sIgE retained a significant independent association with BE tolerance (OR 6.2; 95% CI 1.9-22.8), while the effect of age was attenuated to non-significance. Conclusion: OVM-sIgE was the strongest predictor of BE tolerance in young children with IgE-mediated HEA. Supervised OFC appears safe even in children with prior anaphylaxis. Findings are exploratory and require prospective multicentre validation.
Indexed as
Identifiers
42726140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.